Tokens.com Corp. (SMURF) – Challenging Market Can’t Stop Growth

Wednesday, August 17, 2022

Tokens.com Corp. (SMURF)
Challenging Market Can’t Stop Growth

Tokens.com Corp is a publicly traded company that invests in Web3 assets and businesses focused on the Metaverse, NFTs, DeFi, and gaming based digital assets. Tokens.com is the majority owner of Metaverse Group, one of the world’s first virtual real estate companies. Hulk Labs, a wholly-owned Tokens.com subsidiary, focuses on investing in play-to-earn revenue generating gaming tokens and NFTs. Additionally, Tokens.com owns and stakes crypto assets to earn additional tokens. Through its growing digital assets and NFTs, Tokens.com provides public market investors with a simple and secure way to gain exposure to Web3.

Joe Gomes, Senior Research Analyst, Noble Capital Markets, Inc.

Joshua Zoepfel, Research Associate, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

Second Quarter Results. Tokens.com’s management announced total revenue of $250,714, an increase of $46,724 over the prior year’s $203,990. We had estimated revenue at $450,000. Operating loss was at $502,066 versus last year’s $2.0 million due to a listing expense in the previous year and a decrease in share-based payments. Net loss for the Company was $11.9 million, or $(0.12) per share from a net loss of $8.5 million, or $(0.13) per share, last year.

Challenging Environment but Silver Lining. The Company’s portfolio has seen a large decrease from the crypto market price reductions from the end of the year to the end of the second quarter, as the value of the portfolio has dropped to $6.95 million from $25.17 million. However, management is seeing improved crypto asset pricing since the end of the second quarter. With the Company’s healthy balance sheet and initiatives in the Metaverse and Hulk Labs businesses, we believe the Company is well positioned to ride out the storm….

This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision. 

Release – Comtech to Present at the 12th Annual Midwest IDEAS Investor Conference on August 24th and 25th in Chicago, IL



Comtech to Present at the 12th Annual Midwest IDEAS Investor Conference on August 24th and 25th in Chicago, IL

Research, News, and Market Data on Comtech Telecommunications

MELVILLE, N.Y.–(BUSINESS WIRE)–Aug. 16, 2022– 
August 16, 2022
— Comtech (NASDAQ: CMTL), a leading global provider of next-generation 911 emergency systems and secure wireless communications technologies, today announced that it will participate in the 
Midwest IDEAS Investor Conference on 
Wednesday, August 24, 2022, at The 
Gwen in 
Chicago, IL.
 The Company’s presentation is scheduled to begin at 
12:45PM CT
. The presentation will be webcast and may be accessed through the conference host’s main website: https://www.threepartadvisors.com/midwest and in the investor relations section of the Company’s website: http://www.comtech.com.

Comtech management will provide an overview of the Company and its business opportunities. The Company will also conduct one-on-one meetings with investors throughout the day.

About Comtech

Comtech Telecommunications Corp. is a leading global provider of next-generation 911 emergency systems and secure wireless communications technologies to commercial and government customers around the world. Headquartered in 
Melville, New York and with a passion for customer success, 
Comtech designs, produces and markets advanced and secure wireless solutions. For more information, please visit www.comtech.com.

Forward-Looking
Statements

Certain information in this press release contains statements that are forward-looking in nature and involve certain significant risks and uncertainties. Actual results could differ materially from such forward-looking information. The Company’s 
Securities and Exchange Commission filings identify many such risks and uncertainties. Any forward-looking information in this press release is qualified in its entirety by the risks and uncertainties described in such 
Securities and Exchange Commission filings.

PCMTL

Contacts
Investor
 Relations Robert Samuels 631-962-7102
robert.samuels@comtech.com

Source: 
Comtech Telecommunications Corp.

 


Release – Salem Media Announces Promotion of Jon Latzer



Salem Media Announces Promotion of Jon Latzer

Research, News, and Market Data on Salem Media

August 16, 2022 3:27pm EDT

IRVING, Texas–(BUSINESS WIRE)– 
Salem
Media Group, Inc.
 (NASDAQ: SALM) announced today that it has promoted industry veteran Jon Latzer as Vice President and General Manager of Salem Surround beginning Monday, August 29th. Latzer has spent the last three years at Salem as a Digital Sales Director, three years at Alpha Media in a similar role, and previous roles with CBS Radio and Katz. Latzer will report to Salem Senior Vice President of Broadcast Digital, Jamie Cohen.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220816005766/en/

Jon Latzer (Photo: Business Wire)

Jon Latzer (Photo: Business Wire)

“Jon has been an active, hands-on leader in broadcast for years, but his last six years at Salem and Alpha Media prepared him well for the fast-paced digital world,” said Cohen. “In Jon, we have a strong, experienced General Manager, who will help us take Salem Surround to the next level. Jon was ready for the next adventure in his career, and we are extremely fortunate to have him on the team.”

“Salem Surround has seen incredible revenue and operational growth since its inception. I’m honored to be able to help Salem find unique and creative ways to continue that growth,” Latzer said. “Digital media today is so foundational in our lives and I couldn’t be happier in working with the team here at Salem dedicated to improving the experiences for advertisers and our sales teams.”

Jon’s prior career includes serving as the Director of National Sales at Clear Channel, Director of Digital Ad Sales for Cinesport, Regional Sales Director of Rovi Ad Network, and a National Sales Executive at CBS Local Digital Media.

ABOUT SALEM MEDIA GROUP:

Salem Media Group is America’s leading multimedia company specializing in Christian and conservative content, with media properties comprising radio, digital media and book and newsletter publishing. Each day Salem serves a loyal and dedicated audience of listeners and readers numbering in the millions nationally. With its unique programming focus, Salem provides compelling content, fresh commentary and relevant information from some of the most respected figures across the Christian and conservative media landscape. Learn more about Salem Media Group, Inc. at www.salemmedia.comFacebook and Twitter.

View source version on businesswire.com: 
https://www.businesswire.com/news/home/20220816005766/en/

Evan D. Masyr
Executive Vice President and Chief Financial Officer
(805) 384-4512
evan@salemmedia.com

Source: Salem Media Group, Inc.

Released August 16, 2022


MicroStrategy Doubles Down as Bitcoin Cheerleader



Image Credit: Bloomberg TV (August 4, 2022)


MicroStrategy’s Huge Bitcoin Portfolio is Now Expected to Expand

There is possibly no greater bitcoin (BTC.X) supporter than Michael Saylor. So when he stepped down last week from his position as CEO of MicroStrategy (MSTR), the firm he founded, there was concern among bitcoin investors, speculators, and enthusiasts, that they were losing an advocate and a loud, supportive voice. It turns out their fears may have been premature. Saylor, who now fills a role as the Executive Chairman of the company he ran for over three decades, has more time to extol the benefits of adopting bitcoin in business and individually. It is beginning to look like he will become an even greater voice cheerleading for bitcoin. The new position will actually allow him to double his focus on cryptocurrency at Microstrategy.

MicroStrategy had put more than $4 billion into bitcoin since its first purchase during the second half of 2020. To do this, the data analytics firm stepped outside of its normal business and raised capital by issuing stock, convertible bonds, and corporate debt. It then borrowed against the bitcoin position and increased its exposure.

As bitcoin’s price rose, the company stock price rose in tandem; when bitcoin fell, the stock fell. As a result, when investors were looking for an equity investment with exposure to bitcoin, some bought MSTR. Similarly, when crypto was selling off, they shorted the company. This year has been a rollercoaster ride for stocks and cryptocurrency. This is why there was speculation Microstrategy was preparing to lessen its aggressive posture toward bitcoin. Saylor’s transition out of the CEO role caused speculation that the company would be less positive toward bitcoin.

It has been eight days since Saylor stepped down, and bitcoin supporters, particularly those that would like to see broader adoption by businesses as an accepted currency, have been surprised on the positive side.


Image: Saylor tweet to demonstrate stock outperformance since adopting bitcoin policy.

One of the more obvious signs of Mr. Saylor’s continued support is his Twitter account, with its endless stream of pro-bitcoin messages. Last Wednesday, the former CEO tweeted, “In my next job, I intend to focus more on #Bitcoin.”

The move is now considered more bullish for bitcoin and perhaps helps to further acceptance of all digital assets. Although Saylor himself may not agree with the word “all,” the only asset that he believes will stand the test of time is bitcoin.

MicroStrategy issued word that the company has not sold any bitcoin holdings and doesn’t have any plans to do so. It is making it clear that this change in leadership roles does not indicate a change in the company’s strategy to acquire and hold bitcoin long-term.

According to MicroStrategy’s Q2 earnings report, it held approximately 129,699 bitcoins, for which it paid a total of $3.977 billion. The market value n June 30 was about $2.451 billion.  $2.4 billion is also the total of loans and debt that MicroStrategy has taken on to acquire bitcoin.

Bitcoin was trading for $23,500.30 per coin on Wednesday; the cryptocurrency fell to $17,593 in June, its lowest point since December 2020. Bitcoin reached an all-time high of more than $68,000 per coin in November 2021. Amid discussion of a margin call on a bitcoin-backed loan from Silvergate, Saylor said in June that the company had enough collateral to cover the loan.

MicroStrategy share prices were up 11.82% Wednesday, trading at $311.15. The company’s shares traded as high as $860 in November 2021, when its bitcoin holdings were worth as much as $7 billion.

To be sure, the MicroStrategy bitcoin story is not ending. The reward has been great for those that held MSTR since mid-2020, but the volatility during that time was also substantial.

Paul Hoffman

Managing Editor, Channelchek

Suggested Content



When the History of Bitcoin is Written, This Story Will be in the Book



Cowboys and Cryptocurrency




Dogecoin Group Works to Give Currency Greater Purpose



What Might be in a Portfolio Allocated for a Republican Majority in the House?


Sources

https://theartofthebubble.com/2022/08/michael-saylor-microstrategys-ceo-the-largest-bitcoin-holder-steps-down-after-918-1-m-loss-saylor-will-take-a-new-post-as-executive-chairman/

https://www.microstrategy.com/en/investor-relations

https://twitter.com/saylor?ref_src=twsrc%5Egoogle%7Ctwcamp%5Eserp%7Ctwgr%5Eauthor

https://fortune.com/2022/08/03/michael-saylor-microstrategy-stock-bitcoin-bet-debt-outlook/

https://www.marketwatch.com/story/michael-saylor-drops-microstrategy-ceo-role-heres-what-it-means-for-bitcoin-11659556705?mod=search_headline

Stay up to date. Follow us:

 

Three Reasons Michael Burry May be Holding This One Stock



Image Credit: Kempton (Flickr)


Michael Burry’s Portfolio is Creating More Speculation than Usual

Four times a year, the quarter-end holdings of famous hedge fund manager Dr. Michael J. Burry become public from his firm’s 13-F filing with the SEC. It’s newsworthy because people are interested in this extremely successful investor’s thinking. Of course, the list of public market positions is just a snapshot in time. One day in time, to be exact, so it is possible to read too much into it. The latest 13-F filing, which became public on Monday (August 15) is especially interesting; his entire stock portfolio is one stock. Channelchek featured this company in an article last month; referring back to the article and also a recent Noble Capital Market’s research report, we offer our own three potential reasons why, out of all the securities available on the planet, he may favor this one.


About Scion Asset Management’s One Position

According to the June 30, 2022, SEC filing, Michael Burry’s fund held one position, Geo Group (GEO). These shares represent 0.404% of GEO’s outstanding stock or 501,360 shares. The average price was listed as $6.42 per share.

The quarter-end market value of Scion’s GEO position was $3,309,000. According to Scion’s Form ADV, filed on April 18, 2022, Scion had assets under management of $291,659,289. The GEO position is not likely a significant portion of his entire portfolio, but it represents 100% of the firm’s 13F reportable securities.

Michael Burry first reported owning GEO Group during the fourth quarter of 2020.

The GEO Group, based out of Boca Raton, FL, specializes in owning’ leasing, and managing secure confinement facilities, processing centers, and reentry facilities in the United States and globally. As of December 31, 2021, the company’s worldwide operations included the management and/or ownership of approximately 86,000 beds at 106 secure and community-based facilities, including idle facilities and projects under development.

In addition to owning and operating secure and community facilities, GEO provides compliance technologies, monitoring services, and supervision and treatment programs for community-based parolees, probationers, and pretrial defendants.

For the year ended December 31, 2021, The GEO Group generated approximately 66% of its revenues from the U.S. Secure Services business, 24% from its GEO Care segment, and 10% of revenue from its International Services segment.

 

Company Trajectory

On August 3, in a research note titled, Continuing
to Outperform Expectations
, Noble Capital Markets, Senior Research Analyst Joe
Gomes
set a price target of $15.00 and reported on above-expected operating results during Q2 2022.

Mr. Gomes’ report discussed the drivers of GEO’s growth, “Many parts of GEO’s business continue to show operating strength, driving the better than expected performance.” The analyst also discussed the exceptional growth in revenue of the company’s electronic monitoring division.

The report describes management guidance as “upbeat” for the remainder of 2022. The company could get an extra benefit in the coming months if COVID-related restrictions on occupancy are lifted, thus allowing higher capacity within the same facilities.

Michael Burry’s position is not huge compared to his firm’s AUM. However, what is drawing attention is that out of the universe of stocks, GEO Group is a company he finds interesting enough to have as his only position. It would seem appealing to an investor that the clarity of the company’s direction seems to be improving and positive.

 

Political Winds

Will the mid-term elections in November usher in leadership more friendly to GEO’s business? Six days after President Biden was inaugurated, he signed an executive order to eliminate the use of privately operated criminal detention facilities. Section 2 of this order specifically prohibits renewing any contracts with criminal detention facilities. It looked bleak for the two largest private prison (GEO, CXV) operators in the country.

After the order, the private prison industry shifted gears and focused on the $3 billion market of detaining immigrants. This shift has been positive, and things don’t look as dark for the two largest for-profit prison companies in the U.S., CoreCivic (CXW) and Geo Group (GEO). Each is now making 30% or more of its revenue from U.S. Customs and Immigration (ICE) contracts.

If the Democrats lose the significant power they now have in the legislative branch, it would seem that the party that takes power would almost have a mandate from the public to make changes to many of the less popular moves made over the past year and a half. The southern border situation may be one of the reasons Democrats are likely to have fewer seats.

An argument can be made that new doors may open for private prison companies, and there is not a lot of public competition. Perhaps this is the appeal that keeps Michael Burry involved in GEO Group and why his fund has in the past owned CXW.

 

Portfolio Management

As of the end of Q1 2022, the value of Burry’s position in GEO Group was almost twice as large as shown in the current filing. So the hedge fund manager has liquidated a portion of his GEO position along with all other holdings. This unwinding may not be driven by anything more than what he sees as better opportunities elsewhere. He has also complained in tweets about how much attention his activities generate. It may very well be that with all the shifting in economies, in the U.S. and worldwide, that Burry has taken positions in non-reportable investments.

Earlier this year, after the first quarter, when Michael Burry released his holding information, the headlines all read that he hated Apple (AAPL). This was because he held puts on the company. There can be many
reasons
 a hedge fund would own puts on a company without hating the stock. This latest release brought alarmist headlines about Michael Burry “slashing stocks” in his portfolio and “dumping” everything he owns. He may very well be bearish on every U.S. stock except for one, but this isn’t likely.  As a reminder,  June 30 is just one day on the calendar; his U.S. stock positions could have been quite different by the fourth of July.


Take Away

Michael Burry’s 13F filing for the second quarter showed one holding, an under-the-radar company that has a significant upward trajectory in earnings and growth. The company’s industry had also become challenged when the Biden administration took office since it has successfully found a way to build in a slightly different direction. All indications are that, at minimum, the House of Representatives and possibly the Senate will be more heavily weighted with Republican lawmakers after the upcoming election, the private prison industry could benefit from contracts they may receive with a change in legislative priorities.

If you have not already signed up to receive email from Channelchek with up-to-the-minute research reports on companies like GEO Group and insightful articles, sign-up here.

Paul Hoffman

Managing Editor, Channelchek

Suggested Content



Republicans Likely to Have the Majority in the House – Investors May Want to Pivot Early



Michael Burry’s Stock Market Holdings (Filed May 16, 2022)




Michael Burry vs Cathie Wood is Not an Even Competition



Michael Burry Sees Positive in Elon Musk’s Twitter Stake


Sources

https://www.channelchek.com/company/GEO/research-report/3910

https://whalewisdom.com/filer/scion-asset-management-llc#tabholdings_tab_link

https://channelchek.com/news-channel/What_Might_be_in_a_Portfolio_Allocated_for_a_Republican_Majority_in_the_House_

Stay up to date. Follow us:

 

Release – BioSig Sees Positive Momentum from Sales Pipeline Growth



BioSig Sees Positive Momentum from Sales Pipeline Growth

News and Market Data on BioSig Technologies

August 16, 2022

Westport, CT, Aug. 16, 2022 (GLOBE NEWSWIRE) —

  • Company sees increase in
    medical centers entering into 60-day evaluation agreements
  • Existing customers
    seeing positive results from PURE EP™ System expected to increase
    number of units purchased

BioSig Technologies, Inc. (NASDAQ: BSGM) (“BioSig” or the “Company”), a medical technology company advancing electrophysiology workflow by delivering greater intracardiac signal fidelity through its proprietary signal processing platform, today announced that it is seeing positive momentum from the growth of its sales pipeline, and expects to see an increase in enterprise adoption of its PURE EP™ System  in the coming months.

Since BioSig’s national commercial launch of its PURE EP™ System on July 1st, 2022, the Company’s commercial pipeline has experienced a steady increase in advanced leads and technology adoption across several key regions and centers of excellence. Under the terms of its new leasing program, the Company recently signed a purchase agreement with Kansas City Heart Rhythm Institute at Overland Park Regional Medical Center. In addition, the Company inked its first master services agreement with one of the largest U.S. healthcare systems.

Among several key regions, BioSig’s PURE EP™ System continues to gain interest in hospitals across the Midwest, including new evaluation agreements with the Cleveland Clinic, a leading Medical Center of Excellence, and an additional installation at a leading medical center in Springfield, IL.

“The demand for minimally invasive catheter-based ablation procedures continues to grow. We believe that market demand is high, and expect to see an acceleration of commercial activity in our quarterly results going forward,” commented Kenneth L. Londoner, Chairman and CEO of BioSig Technologies, Inc.

BioSig’s commercial momentum is supported by its recent decision to streamline the PURE EP™ System evaluation period from 180-360 days to 60-days. The Company has also implemented a new leasing program to help expedite the acquisition of Pure EP’s superior signal processing capabilities and shortens the sales cycle.  Consistent with its stated commercial strategy, BioSig is prioritizing the growth of its robust sales team, including the recent appointment of a new sales leader who will cover the COLT states (Colorado, Oklahoma, Louisiana, and Texas).

“By shortening our evaluation period and providing flexible paths to purchase, we are meeting the demands of physicians and supply chain management, ensuring that superior signal processing technology is within reach. We’re pleased to be exploring opportunities for repeat business and additional unit placement with many of our existing accounts,” commented Gray Fleming, Chief Commercialization Officer, BioSig Technologies, Inc.

Looking further ahead, the Company will be participating in several key industry conferences and events, including the 2022 Kansas City
Heart Rhythm Symposium,
 taking place at the end of the month and the Cleveland Clinic
Global EP Summit 2022
 in September, where BioSig will serve as sponsor at the annual global summit.

The Company is also expanding its clinical research pipeline, including the recent commencement of a physician-initiated research protocol that will analyze the signals acquired by its PURE EP™ System during Radiofrequency (RF) ablation. Led by Dhanunjaya DJ Lakkireddy, MD, Medical Director for the Kansas City Heart Rhythm Institute, the single center study underway at Overland Park Regional Medical Center, is officially registered with clinicaltrials.gov [NCT05464537], and includes 30 participants with paroxysmal atrial fibrillation (AF) undergoing pulmonary vein isolation (PVI).

About BioSig Technologies
BioSig Technologies is a medical technology company commercializing a proprietary biomedical signal processing platform designed to improve signal fidelity and uncover the full range of ECG and intra-cardiac signals (www.biosig.com).

The Company’s first product, PURE EP™ System, is a novel signal processing and acquisition platform designed to extract advanced diagnostic and therapeutic data that enhances physician workflow and increases throughput. PURE EP™ was engineered to address the limitations of existing EP technologies by empowering physicians with superior signals and actionable insights.

The Company is in a national commercial launch of the PURE EP™ System. The technology is in regular use in some of the country’s leading centers of excellence, including Mayo Clinic, and Texas Cardiac Arrhythmia Institute at St. David’s Medical Center.

Clinical data acquired by the PURE EP™ System in a multi-center study at centers of excellence including Texas Cardiac Arrhythmia Institute at St. David’s Medical Center  was recently published in the Journal of Cardiovascular Electrophysiology and is available electronically with open access via the Wiley Online
Library
. Study results showed 93% consensus across the blinded reviewers with a 75% overall improvement in intracardiac signal quality and confidence in interpreting PURE EP(T.M.) signals over conventional sources.

Forward-looking
Statements

This press release contains “forward-looking statements.” Such statements may be preceded by the words “intends,” “may,” “will,” “plans,” “expects,” “anticipates,” “projects,” “predicts,” “estimates,” “aims,” “believes,” “hopes,” “potential” or similar words. Forward- looking statements are not guarantees of future performance, are based on certain assumptions and are subject to various known and unknown risks and uncertainties, many of which are beyond the Company’s control, and cannot be predicted or quantified and consequently, actual results may differ materially from those expressed or implied by such forward-looking statements. Such risks and uncertainties include, without limitation, risks and uncertainties associated with (i) market conditions and the Company’s intended use of proceeds, (ii) the geographic, social and economic impact of COVID-19 on our ability to conduct our business and raise capital in the future when needed, (iii) our inability to manufacture our products and product candidates on a commercial scale on our own, or in collaboration with third parties; (iv) difficulties in obtaining financing on commercially reasonable terms; (v) changes in the size and nature of our competition; (vi) loss of one or more key executives or scientists; and (vii) difficulties in securing regulatory approval to market our products and product candidates. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in the Company’s filings with the Securities and Exchange Commission (SEC), including the Company’s Annual Report on Form 10-K and its Quarterly Reports on Form 10-Q. Investors and security holders are urged to read these documents free of charge on the SEC’s website at http://www.sec.gov. The Company assumes no obligation to publicly update or revise its forward-looking statements as a result of new information, future events or otherwise.


Andrew Ballou
BioSig Technologies, Inc.
Vice President, Investor Relations
55 Greens Farms Road
Westport, CT 06880
aballou@biosigtech.com
203-409-5444, x133
 

Primary Logo

Source: BioSig Technologies, Inc.

Released
August 16, 2022

 


Release – Allegiant to Participate at the Precious Metals Summit Beaver Creek Conference



Allegiant to Participate at the Precious Metals Summit Beaver Creek Conference

Research, News, and Market Data on Allegiant Gold

Reno, Nevada
/August 16, 2022 – Allegiant Gold Ltd. (“Allegiant” or the “Company”) (AUAU:
TSX-V) (AUXXF: OTCQX) 
is pleased to announce management’s participation in the Precious Metals Summit Conference hosted in Beaver Creek, CO from September 13-16, 2022. 

The Precious Metals Summit is one of the most comprehensive conferences for established producers, developers and exploration companies throughout the world.  Numerous institutional and corporate executives in the precious metals industry have historically attended this prestigious event.  Allegiant is proud to once again be one of the companies attending the event. 

ABOUT ALLEGIANT
Allegiant owns 100% of 10 highly-prospective gold projects in the United States, 7 of which are located in the mining-friendly jurisdiction of Nevada. Three of Allegiant’s projects are farmed-out, providing for cost reductions and cash-flow. Allegiant’s flagship, district-scale Eastside project hosts a large and expanding gold resource and is located in an area of excellent infrastructure. Preliminary metallurgical testing indicates that both oxide and sulphide gold mineralization at Eastside is amenable to heap leaching.

ON BEHALF OF THE BOARD
Peter Gianulis
CEO

For more information contact:
Investor Relations
(604) 634-0970 or
1-888-818-1364

ir@allegiantgold.com


Genprex (GNPX) – REQORSA Approved For Dose Escalation In Phase 1/2 Trial

Tuesday, August 16, 2022

Genprex (GNPX)
REQORSA Approved For Dose Escalation In Phase 1/2 Trial

Robert LeBoyer, Vice President, Research Analyst, Life Sciences , Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

Sufficient Safety Shown In First Cohort.  Genprex announced that the first cohort from its Phase 1/2 Acclaim-1 trial in non-small cell lung cancer (NSCLC) has shown sufficient safety to allow treatment of a second cohort at a higher dose. This approval from the Safety Review Committee (SRC) after it analyzed patient data in the first cohort. Genprex expects all three cohorts in the Phase 1 portion to be completed by YE22.

Mechanism Of Action Could Improve Patient Survival.  The Acclaim-1 study is Phase 1/2 trial testing the combination of REQORSA with Tagrisso (osimertinib) in non-small cell lung cancer (NSCLC).  This combines Tagrisso’s action as an EGF inhibitor with Requorsa’s delivery of the TUSC2 cancer suppressor gene.  REQORSA adds the inhibition of several pathways leading to tumor growth and proliferation, and restores pathways that defend against cancer.  The REQORSA combination has received Fast-Track designation for NSCLC from the FDA….

This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision. 

Schwazze (SHWZ) – A Record Quarter, But What’s Next?

Tuesday, August 16, 2022

Schwazze (SHWZ)
A Record Quarter, But What’s Next?

Schwazze (OTCQX:SHWZ, NEO:SHWZ) is building a premier vertically integrated regional cannabis company with assets in Colorado and New Mexico and will continue to take its operating system to other states where it can develop a differentiated regional leadership position. Schwazze is the parent company of a portfolio of leading cannabis businesses and brands spanning seed to sale. The Company is committed to unlocking the full potential of the cannabis plant to improve the human condition. Schwazze is anchored by a high-performance culture that combines customer-centric thinking and data science to test, measure, and drive decisions and outcomes. The Company’s leadership team has deep expertise in retailing, wholesaling, and building consumer brands at Fortune 500 companies as well as in the cannabis sector. Schwazze is passionate about making a difference in our communities, promoting diversity and inclusion, and doing our part to incorporate climate-conscious best practices.

Joe Gomes, Senior Research Analyst, Noble Capital Markets, Inc.

Joshua Zoepfel, Research Associate, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

2Q22 Results. Revenue for the quarter totaled $44.3 million, up from $31.8 million in the first quarter and $30.7 million a year ago. The increase was mostly due to acquisitions as the Colorado market continued to experience softness from the 2021 COVID highs. Adjusted EBITDA was $15.0 million in the quarter, up from $10.0 million a year ago. Schwazze reported operating income of $9 million and net income of $32.1 million, or $0.24 per diluted share, versus $4.4 million and $0.08 last year. We had forecast revenue of $39 million and a net loss of $1.6 million, or $0.03 per share.

Metrics. For the sixth consecutive quarter, Schwazze outpaced the Colorado industry, this time by 11%, but ongoing weakness in the Colorado market resulted in declines in key performance metrics. Colorado two year stacked IDs for same store sales in the second quarter were up 1.8%, although one year were down 12.7%. The same measurements for New Mexico were up 41% and 30.4%, respectively. Average basket size fell in both markets….

This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision. 

Maple Gold Mines (MGMLF) – A Harbinger of Things to Come?

Tuesday, August 16, 2022

Maple Gold Mines (MGMLF)
A Harbinger of Things to Come?

Mark Reichman, Senior Research Analyst, Natural Resources, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

Phase II drilling at Eagle. Maple Gold reported initial assay results from the first hole of the Phase II drill program at its 100%-controlled Eagle Mine property in Quebec. The Phase II program consisted of four master diamond drill holes and one daughter drill hole totaling 4,700 meters to test extensions of mineralization along and beneath the past-producing Eagle-Telbel mine trend. To date, approximately 16,450 meters of the approximately 30,000 meters of drilling planned across the company’s Quebec project portfolio has been completed. Eagle assays have been reported for approximately 5,400 meters of drilling representing 59% of Eagle drilling completed.

Results from the first hole broaden the lens. Hole EM-22-009 intersected 11.4 grams of gold per tonne over three meters, including 24.4 grams of gold per tonne over one meter to the north of the Eagle-Telbel mine horizon in the hanging wall microgabbro. The results underscore the potential for additional styles of gold mineralization at Eagle and broader gold distribution and have implications for the company’s exploration targeting, including the Phase III drilling program later in the year. …

This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision. 

Cocrystal Pharma (COCP) – 2Q Reported With Influenza and COVID-19 Product Updates

Tuesday, August 16, 2022

Cocrystal Pharma (COCP)
2Q Reported With Influenza and COVID-19 Product Updates

Cocrystal Pharma, Inc. is a clinical-stage biotechnology company discovering and developing novel antiviral therapeutics that target the replication process of influenza viruses, coronaviruses (including SARS-CoV-2), hepatitis C viruses and noroviruses. Cocrystal employs unique structure-based technologies and Nobel Prize-winning expertise to create first- and best-in-class antiviral drugs. For further information about Cocrystal, please visit www.cocrystalpharma.com.

Robert LeBoyer, Vice President, Research Analyst, Life Sciences , Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

2Q Included One-Time Charges.  Cocrystal reported a loss of $24.4 million or $(0.25) per share, including a write-off of goodwill for $19.1 million and a legal settlement expense of $1.6 million.  Operating expenses excluding these charges were $3.7 million, compared with our estimated operating expenses of $3.8 million.  The company ended the quarter with $51.0 million in cash.

Influenza Program Reported First Data With More Expected Later in 2022.  The company reported that data from CC-42344, its oral PB2 inhibitor that blocks a polymerase enzyme needed for viral replication.  Data from a single-ascending dose study supporting the once-daily dosing schedule.  Additional results from the Phase 1 study enrolling healthy volunteers in Australia are expected to be announced later this year.   …

This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision. 

Blackboxstocks (BLBX) – Reports Second Quarter Results

Tuesday, August 16, 2022

Blackboxstocks (BLBX)
Reports Second Quarter Results

Blackboxstocks, Inc. is a financial technology and social media hybrid platform offering real-time proprietary analytics and news for stock and options traders of all levels. Our web-based software employs “predictive technology” enhanced by artificial intelligence to find volatility and unusual market activity that may result in the rapid change in the price of a stock or option. Blackbox continuously scans the NASDAQ, New York Stock Exchange, CBOE, and all other options markets, analyzing over 10,000 stocks and up to 1,500,000 options contracts multiple times per second. We provide our users with a fully interactive social media platform that is integrated into our dashboard, enabling our users to exchange information and ideas quickly and efficiently through a common network. We recently introduced a live audio/video feature that allows our members to broadcast on their own channels to share trade strategies and market insight within the Blackbox community. Blackbox is a SaaS company with a growing base of users that spans 42 countries; current subscription fees are $99.97 per month or $959.00 annually. For more information, go to: www.blackboxstocks.com .

Joe Gomes, Senior Research Analyst, Noble Capital Markets, Inc.

Joshua Zoepfel, Research Associate, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

2Q22 Results. Revenue was $1.4 million, down from $1.46 million a year ago, but up from $1.272 million in the first quarter. Our estimate was $1.5 million. The Company reported a loss of $1.3 million, or $0.10 per share, in the quarter, compared to a net loss of $243,336, or $0.03 per share, last year. Our estimate called for a loss of $996,000, or $0.08 per share.

Economic Headwinds. Challenging financial markets and an overall difficult economic environment weighed on results. Expenses increased as the Company continues to invest in both product development and marketing initiatives. Average member count for the quarter was 6,181, up from 5,709 at the end of the March quarter. We anticipate additional marketing spend in 2H22.

This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision. 

BioSig Technologies (BSGM) – 2Q 2022 released; No Big Surprises, But Looking Forward

Tuesday, August 16, 2022

BioSig Technologies (BSGM)
2Q 2022 released; No Big Surprises, But Looking Forward

BioSig Technologies is a medical technology company commercializing a proprietary biomedical signal processing platform designed to improve signal fidelity and uncover the full range of ECG and intra-cardiac signals (www.biosig.com). The Company’s first product, PURE EP(TM) System is a computerized system intended for acquiring, digitizing, amplifying, filtering, measuring and calculating, displaying, recording and storing of electrocardiographic and intracardiac signals for patients undergoing electrophysiology (EP) procedures in an EP laboratory.

Gregory Aurand, Senior Research Analyst, Healthcare Services & Medical Devices, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

2Q 2022 results were released. BioSig released second quarter results in its 10Q filing yesterday. As we previously removed second quarter PURE EP unit revenues (see note dated July 8, 2022), top-line reported in the quarter was no surprise.  The Company did generate $8,000 in service revenue in the quarter.

Expenses lower than expected. We had expected $6.8 million in operating expenses in the quarter, but BioSig reported $5.7 million due to General and Administrative expenses being $1.2 million lower. Diluted share count was 264k higher than our estimate at 39.823 million.  Net loss per share of $0.15 beat our estimate of a loss of $0.17….

This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision.